An Exploratory Study of SHR-1701 (Rilafucept alfa) Combined with Famitinib and GEMOX as First-Line Therapy for Unresectable Advanced Biliary Tract Cancers

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 1d801510f2d64e0c4c37160fe0e80d08cdab479d
First added on: Sep 12, 2026